ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Shaobo Zhang
Matched on ORCID iD 0000-0001-5413-5064; OpenAlex author ID A5013511830. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2023: 1 paper · 2024: none · 2025: 3 papers · 2026: 1 paper
Papers 5
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-5716↗
- Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217523↗
- N-acetyltransferase 10 Promotes Pancreatic Cancer Progression Through ZEB1/MT1-MMP Axis. Co-author DOI 10.1097/mpa.0000000000002492↗
- ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL16. Co-author DOI 10.1172/jci195970↗
- Protocadherin-1 serves as a prognostic biomarker and promotes pancreatic cancer progression by suppressing CD8+ T cell infiltration through CCL5-CCR5 axis. First author PMID 38058826↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Fangxia Wang · 4 shared papers, 2023–2025 · strength 0.88
- Paper N-acetyltransferase 10 Promotes Pancreatic Cancer Progression Through ZEB1/MT1-MMP Axis. DOI 10.1097/mpa.0000000000002492↗
- Paper ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL… DOI 10.1172/jci195970↗
- Paper Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. DOI 10.1016/j.canlet.2025.217523↗
- Yumeng Hu · 3 shared papers, 2025 · strength 0.71
- Paper N-acetyltransferase 10 Promotes Pancreatic Cancer Progression Through ZEB1/MT1-MMP Axis. DOI 10.1097/mpa.0000000000002492↗
- Paper ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL… DOI 10.1172/jci195970↗
- Paper Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. DOI 10.1016/j.canlet.2025.217523↗
- Mingyang Liu · 3 shared papers, 2025 · strength 0.71
- Paper N-acetyltransferase 10 Promotes Pancreatic Cancer Progression Through ZEB1/MT1-MMP Axis. DOI 10.1097/mpa.0000000000002492↗
- Paper ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL… DOI 10.1172/jci195970↗
- Paper Tumor-derived miR-203a-3p potentiates muscle wasting by inducing muscle ferroptosis in pancreatic cancer. DOI 10.1016/j.canlet.2025.217523↗
- Zhijun Zhou · 2 shared papers, 2025–2026 · strength 0.49
- Paper Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic … DOI 10.1158/0008-5472.can-25-5716↗
- Paper ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL… DOI 10.1172/jci195970↗
- Haoran Qi · 2 shared papers, 2025–2026 · strength 0.49
- Paper Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic … DOI 10.1158/0008-5472.can-25-5716↗
- Paper ZEB1 promotes chemoimmunotherapy resistance in pancreatic cancer models by downregulating chromatin acetylation of CXCL… DOI 10.1172/jci195970↗
- Min Li · 1 shared paper, 2026 · strength 0.26
- Mingyang Liu · 1 shared paper, 2026 · strength 0.26
- Hao Yuan · 1 shared paper, 2026 · strength 0.26
- Courtney W. Houchen · 1 shared paper, 2026 · strength 0.26
- Min Li · 1 shared paper, 2025 · strength 0.22
- Wenming Wu · 1 shared paper, 2025 · strength 0.22
- Zhihua Liu · 1 shared paper, 2025 · strength 0.22
- Yongxing Du · 1 shared paper, 2025 · strength 0.22
- Jingyong Xu · 1 shared paper, 2025 · strength 0.22
- Hui‐Ju Wang · 1 shared paper, 2023 · strength 0.17
- Xiaohao Zheng · 1 shared paper, 2023 · strength 0.17
- Zhichen Jiang · 1 shared paper, 2023 · strength 0.17
- Mingyang Liu · 1 shared paper, 2023 · strength 0.17
- Weiwei Jin · 1 shared paper, 2023 · strength 0.17
- Yiping Mou · 1 shared paper, 2023 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.